Targeted therapy for prostate cancer: The Memorial Sloan-Kettering Cancer Center approach Conference Paper

  


Authors: Slovin, S. F.; Livingston, P. O.; Rosen, N.; Sepp-Lorenzino, L.; Kelly, W. K.; Mendelsohn, J.; Scher, H. I.
Title: Targeted therapy for prostate cancer: The Memorial Sloan-Kettering Cancer Center approach
Conference Title: Hormone-Refractory Prostate Cancer: An Emerging Epidemic
Abstract: Carcinoma of the prostate represents a wide range of diseases with differing prognoses. A key to selecting treatment depends on the ability to predict the natural history of the disease for the individual. Thus far, nonhormonal approaches have not demonstrated a survival advantage in randomized comparisons and, clearly, innovative approaches are needed. The clinical trials program developed at Memorial Sloan-Kettering Cancer Center is based on specific manifestations and specific targets of the disease and the predicted prognosis, using prostate-specific antigen and acid phosphatase changes as biomarkers of progression and response. In patients with minimal disease who have received local treatments but progressed systemically, we are studying methods aimed at stimulating their immune systems either by nonspecific immunopotentiation or specific immunization to specific glycoprotein or carbohydrate targets on the cancer cells, or to antigrowth factor receptor antibody aimed at blocking the specific signalling pathways that contribute to hormonal failure. These and other approaches provide an opportunity to treat this disease while maintaining an acceptable quality of life for patients.
Keywords: signal transduction; androgen; clinical trial; doxorubicin; cancer growth; antineoplastic agents; conference paper; prostate specific antigen; animals; cancer immunotherapy; quality of life; epidermal growth factor receptor; enzyme inhibitor; monoclonal antibody; prostate cancer; prostate-specific antigen; prostatic neoplasms; antibodies, monoclonal; immunotherapy; gamma interferon; cancer vaccine; cancer immunization; radioimmunotherapy; transforming growth factor alpha; neoplasms, hormone-dependent; immunoglobulin m antibody; mucin; receptors, growth factor; acid phosphatase; qs 21; receptor antibody; humans; prognosis; human; male; priority journal; monoclonal antibody cc49
Journal Title Seminars in Oncology
Volume: 23
Issue: 6 Suppl. 14
Conference Dates: 1996 May 22
Conference Location: Philadelphia, PA
ISBN: 0093-7754
Publisher: Elsevier Inc.  
Date Published: 1996-12-01
Start Page: 41
End Page: 48
Language: English
PUBMED: 8996585
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-0030471920&partnerID=40&md5=5202c814350dbdd2cce7ac887ad857d6
Notes: Conference Paper -- Export Date: 22 November 2017 -- Source: Scopus
Citation Impact
What is Dimensions Citation Badge?
MSK Authors
  1. Neal Rosen
    425 Rosen
  2. Susan Slovin
    254 Slovin
  3. William K Kelly
    115 Kelly
  4. Philip O Livingston
    228 Livingston
  5. Howard Scher
    1129 Scher
  6. Laura Sepp-Lorenzino
    40 Sepp-Lorenzino
  7. John Mendelsohn
    128 Mendelsohn
Related MSK Work